샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777522

세계의 망막정맥폐쇄증 치료 시장

Retinal Vein Occlusion Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 373 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

망막정맥폐쇄증 치료 세계 시장은 2030년까지 39억 달러에 달할 전망

2024년에 28억 달러로 추정되는 망막정맥폐쇄증 치료 세계 시장은 2024-2030년 분석 기간 동안 CAGR 6.0%로 성장하여 2030년에는 39억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 망막중심정맥폐쇄증은 CAGR 6.9%를 기록하며 분석 기간 종료까지 29억 달러에 달할 것으로 예측됩니다. 망막분지정맥폐쇄증 부문의 성장률은 분석 기간 동안 CAGR 4.0%로 추정됩니다.

미국 시장은 7억 4,940만 달러로 추정, 중국은 CAGR 9.7%로 성장 예측

미국의 망막정맥폐쇄증 치료 시장은 2024년에 7억 4,940만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년 분석 기간 동안 CAGR 9.7%로 성장하여 2030년까지 8억 410만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.9%와 6.0%로 예측됩니다. 유럽에서는 독일이 CAGR 4.0%로 성장할 것으로 예측됩니다.

세계 망막정맥폐쇄증 치료 시장 - 주요 동향 및 촉진요인 정리

효과적인 망막정맥폐쇄증(RVO) 치료의 중요성이 대두되고 있는 이유는 무엇일까?

망막정맥폐쇄증(RVO)은 시력장애의 주요 원인으로 고혈압, 당뇨병, 심혈관질환 등 기저질환과 관련이 있는 경우가 많습니다. RVO는 황반부종, 신생혈관 녹내장 등 심각한 합병증을 유발할 수 있어 효과적인 치료 전략에 대한 수요가 증가하고 있습니다. 약물 치료, 레이저 치료, 수술적 개입의 발전은 환자의 결과를 개선하고 시력 악화를 예방하는 데 도움이 되고 있습니다. 고령화 사회의 진전과 대사성 질환의 유병률 증가는 전 세계적으로 RVO 사례의 증가에 기여하고 있습니다. 그 결과, 의료 서비스 제공자와 연구자들은 보다 타겟이 명확하고 장기적인 치료법 개발에 집중하고 있습니다.

기술의 발전은 RVO의 치료 결과를 어떻게 개선하고 있는가?

항VEGF(혈관내피성장인자) 치료의 개발로 RVO와 관련된 황반부종 치료 상황이 완전히 바뀌었고, 망막 부종이 크게 감소하여 시력이 개선되었습니다. 서방형 코르티코스테로이드 임플란트도 도입되어 적은 주사 횟수로 장기적인 효과를 얻을 수 있게 되었습니다. 또한, 마이크로 펄스 레이저 요법을 포함한 레이저 광응고 기술의 발전으로 부작용을 줄인 보다 정확한 치료 옵션이 제공되고 있습니다. AI 기반 진단 도구와 망막 영상 시스템은 조기 발견과 개별화된 치료 계획을 강화하여 RVO 환자에게 적시에 개입할 수 있도록 돕습니다. 또한, 줄기세포 치료를 포함한 새로운 재생의료 접근법은 손상된 망막 조직을 복구하고 장기적인 예후를 개선할 수 있을 것으로 기대되고 있습니다.

RVO 치료 수요를 견인하는 시장 동향은?

항 VEGF 주사와 레이저 치료를 통합한 병용요법의 채택이 증가하고 있으며, 치료 효과를 높이는 동시에 의료 개입의 빈도를 줄이고 있습니다. 원격 안과 서비스의 확대로 조기 진단과 원격 모니터링이 용이해져 환자 관리가 향상되고 있습니다. 또한, 스마트폰을 이용한 망막 영상 진단 등 재택 시력 모니터링 솔루션의 등장으로 환자들은 자신의 눈 건강 상태를 파악하고 적시에 진료를 받을 수 있게 되었습니다. 정부 지원 망막 질환 검진 프로그램 및 의료비 환급 정책은 시장 성장을 더욱 촉진하고 있습니다. 유전자 치료, 신경 보호 등 새로운 치료법 연구가 진행됨에 따라 RVO 치료 시장은 빠르게 발전하고 있습니다.

RVO 치료 시장의 주요 성장 촉진요인은?

세계 망막정맥폐쇄증 치료 시장의 성장은 당뇨병과 고혈압의 증가, 약리요법의 발전, 망막영상기술의 향상에 힘입어 성장하고 있습니다. 항VEGF 요법이 RVO 관련 합병증에 대한 1차 치료제로 널리 채택되고 있는 것이 시장 확대에 크게 기여하고 있습니다. 또한, 장시간 작용하는 약물전달시스템이 사용 가능해짐에 따라 환자의 순응도가 향상되고 치료부담이 줄어들고 있습니다. 신흥 시장에서의 의료 접근성 확대와 정부 주도의 시력 보호에 대한 노력은 수요를 더욱 가속화시키고 있습니다. RVO 치료 시장은 새로운 치료 혁신의 출현으로 전 세계 환자들에게 개선된 솔루션을 제공하면서 지속적인 성장이 예상됩니다.

부문

질환 유형(망막중심정맥폐쇄증, 망막분지정맥폐쇄증), 치료법(항혈관내피인자약, 코르티코스테로이드 약, 기타), 최종사용자(병원·클리닉, 소매 약국, 기타)

조사 대상 기업 사례

  • AbbVie Inc.
  • Aerie Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Annexin Pharmaceuticals AB
  • Bayer AG
  • Biocon Biologics Ltd
  • Bristol-Myers Squibb Company
  • Carl Zeiss Meditec AG
  • Chugai Pharmaceutical Co., Ltd
  • Ellex Medical Lasers Ltd
  • EyePoint Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.(a member of the Roche Group)
  • GlaxoSmithKline plc
  • IRIDEX Corporation
  • Johnson & Johnson Services, Inc.
  • Kodiak Sciences Inc.
  • Lumenis Ltd.
  • Merck & Co., Inc.
  • NIDEK CO., LTD.

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.05

Global Retinal Vein Occlusion Treatment Market to Reach US$3.9 Billion by 2030

The global market for Retinal Vein Occlusion Treatment estimated at US$2.8 Billion in the year 2024, is expected to reach US$3.9 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Central Retinal Vein Occlusion, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Branch Retinal Vein Occlusion segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$749.4 Million While China is Forecast to Grow at 9.7% CAGR

The Retinal Vein Occlusion Treatment market in the U.S. is estimated at US$749.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$804.1 Million by the year 2030 trailing a CAGR of 9.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Retinal Vein Occlusion Treatment Market - Key Trends & Drivers Summarized

Why Is Effective Retinal Vein Occlusion (RVO) Treatment Becoming More Important?

Retinal vein occlusion (RVO) is a leading cause of vision impairment, often associated with underlying conditions such as hypertension, diabetes, and cardiovascular diseases. As RVO can lead to severe complications, including macular edema and neovascular glaucoma, the demand for effective treatment strategies has increased. Advances in pharmacotherapy, laser therapy, and surgical interventions have improved patient outcomes, helping to prevent further vision deterioration. The growing aging population, along with the increasing prevalence of metabolic disorders, has contributed to a rise in RVO cases worldwide. As a result, healthcare providers and researchers are focusing on developing more targeted and long-lasting treatment options.

How Are Technological Advancements Improving RVO Treatment Outcomes?

The development of anti-VEGF (vascular endothelial growth factor) therapy has transformed the treatment landscape for RVO-related macular edema, significantly reducing retinal swelling and improving visual acuity. Sustained-release corticosteroid implants have also been introduced, offering long-term benefits with fewer injections. Additionally, advancements in laser photocoagulation techniques, including micropulse laser therapy, have provided more precise treatment options with reduced side effects. AI-powered diagnostic tools and retinal imaging systems are enhancing early detection and personalized treatment planning, ensuring timely interventions for RVO patients. Moreover, emerging regenerative medicine approaches, including stem cell therapy, hold promise for restoring damaged retinal tissues and improving long-term prognosis.

What Market Trends Are Driving the Demand for RVO Treatments?

The increasing adoption of combination therapies, integrating anti-VEGF injections with laser treatments, has enhanced treatment efficacy while reducing the frequency of medical interventions. The expansion of teleophthalmology services has facilitated early diagnosis and remote monitoring, improving patient management. Additionally, the rise of home-based vision monitoring solutions, such as smartphone-based retinal imaging, is empowering patients to track their eye health and seek timely medical attention. Government-funded retinal disease screening programs and healthcare reimbursement policies are further driving market growth. As research continues to explore novel therapeutic approaches, including gene therapy and neuroprotection, the RVO treatment market is evolving rapidly.

What Are the Key Growth Drivers of the RVO Treatment Market?

The growth in the global retinal vein occlusion treatment market is driven by increasing incidences of diabetes and hypertension, advancements in pharmacological therapies, and improvements in retinal imaging technology. The widespread adoption of anti-VEGF therapy as a first-line treatment for RVO-related complications has significantly contributed to market expansion. Additionally, the growing availability of long-acting drug delivery systems is improving patient compliance and reducing treatment burden. The expansion of healthcare access in emerging markets, along with government-led initiatives for vision care, is further accelerating demand. As new therapeutic innovations continue to emerge, the RVO treatment market is expected to witness sustained growth, offering improved solutions for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Retinal Vein Occlusion Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion); Treatment (Anti-vascular Endothelial Factor, Corticosteroid Drugs, Others); End-Use (Hospital & Clinics, Retail Pharmacy, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Aerie Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Annexin Pharmaceuticals AB
  • Bayer AG
  • Biocon Biologics Ltd
  • Bristol-Myers Squibb Company
  • Carl Zeiss Meditec AG
  • Chugai Pharmaceutical Co., Ltd
  • Ellex Medical Lasers Ltd
  • EyePoint Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc. (a member of the Roche Group)
  • GlaxoSmithKline plc
  • IRIDEX Corporation
  • Johnson & Johnson Services, Inc.
  • Kodiak Sciences Inc.
  • Lumenis Ltd.
  • Merck & Co., Inc.
  • NIDEK CO., LTD.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Retinal Vein Occlusion Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Prevalence of Hypertension and Cardiovascular Risk Factors Drives Incidence of Retinal Vein Occlusion
    • Rising Demand for Anti-VEGF and Corticosteroid Injections Throws the Spotlight on Pharmacologic Management
    • Expansion of Patient Access to Intravitreal Therapies Strengthens Business Case for RVO Treatment Portfolios
    • Development of Sustained-Release Implants Enhances Adherence and Reduces Treatment Burden
    • Clinical Research on Combination Therapies Propels Innovation in Managing Complex and Resistant RVO Cases
    • Integration of OCT Imaging and Angiography in Diagnostic Pathways Enhances Early Detection and Monitoring
    • Rising Emphasis on Personalized Therapy Selection Based on Occlusion Type Supports Precision Medicine Approaches
    • Increased Awareness Campaigns Around Ocular Stroke and Vascular Health Drives Early Intervention Rates
    • Regulatory Approvals for Long-Acting Formulations and New Drug Classes Expand Therapeutic Options
    • Expansion of Ophthalmology Clinics and Ambulatory Injection Facilities Accelerates Market Accessibility
    • Technological Advancements in Intraocular Injection Devices Improve Accuracy and Reduce Complications
    • Growing Pipeline of Novel Biologics and Biosimilars Enhances Competitive Landscape and Affordability
    • Inclusion of RVO Treatment in Public Health Eye Screening Programs Broadens Patient Outreach
    • Use of Adjunctive Laser Therapy in Ischemic RVO Supports Multimodal Treatment Strategies
    • Rising Research on Inflammation and Microvascular Involvement Spurs New Mechanism-Targeted Drugs
    • Shift Toward Evidence-Based Retreatment Protocols Improves Long-Term Visual Outcomes
    • Strategic Collaborations Between Pharma Companies and Retinal Specialists Drive Drug Adoption
    • Real-World Data and Clinical Registries Strengthen Post-Market Evidence for RVO Therapies
    • Reimbursement Expansion and Tiered Access Pricing Models Boost Treatment Uptake in Developing Regions
    • Global Burden of Vision Loss From RVO Accelerates Innovation in Both Diagnostic and Therapeutic Modalities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Retinal Vein Occlusion Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Central Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Central Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Central Retinal Vein Occlusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Branch Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Branch Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Branch Retinal Vein Occlusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-vascular Endothelial Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-vascular Endothelial Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Anti-vascular Endothelial Factor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Corticosteroid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제